Cambridge Investment Research Advisors’s TG Therapeutics TGTX Stock Holding History

Cambridge Investment Research Advisors’s Portfolio TGTX Stock Details TGTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$667K	Sell	12,132 -964	-7%	-$39.5K	﹤0.01%	2689
2026 Q1	$435K	Sell	13,096 -24	-0.2%	-$715	﹤0.01%	2934
2025 Q4	$391K	Buy	13,120 +3,987	+44%	+$130K	﹤0.01%	2951
2025 Q3	$330K	Buy	+9,133	New	+$301K	﹤0.01%	3035
2021 Q3	–	Sell	-7,182	Closed	-$279K	–	3203
2021 Q2	$279K	Sell	7,182 -11,497	-62%	-$451K	﹤0.01%	2526
2021 Q1	$900K	Buy	18,679 +453	+2%	+$21.8K	﹤0.01%	1503
2020 Q4	$948K	Buy	18,226 +247	+1%	+$8.35K	0.01%	1341
2020 Q3	$481K	Buy	+17,979	New	+$414K	﹤0.01%	1625

Other funds holding TGTX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

CAM

Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return

Cambridge Investment Research Advisors's TGTX Position: Q2 2026 in Review

Cambridge Investment Research Advisors reduced its TG Therapeutics (TGTX) stake by 7.4% in Q2 2026, selling an estimated $39.5K and leaving 12,132 shares worth $667K. The position accounts for ﹤0.01% of the portfolio, ranked #2689.

Cambridge Investment Research Advisors first reported a position in TGTX in Q3 2020 and has held it in 8 quarters since. The position peaked at $948K in Q4 2020. 427 funds tracked by Wall St. Rank hold TGTX as of Q2 2026.

Cambridge Investment Research Advisors held 12,132 shares of TG Therapeutics worth $667K as of Q2 2026.
Cambridge Investment Research Advisors sold 964 TG Therapeutics shares in Q2 2026, an estimated $39.5K.
TG Therapeutics made up ﹤0.01% of Cambridge Investment Research Advisors's portfolio in Q2 2026, its #2689 holding.
Cambridge Investment Research Advisors first reported a position in TG Therapeutics in Q3 2020 and has held it in 8 quarters since.
Cambridge Investment Research Advisors's TG Therapeutics position peaked at $948K in Q4 2020.
427 funds tracked by Wall St. Rank held TG Therapeutics as of Q2 2026.

Based on Cambridge Investment Research Advisors's 13F filing for Q2 2026, filed 27 Jul 2026.